Ginkgo Bioworks Holdings, Inc. (DNA)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cell Engineering Revenue	95.01M	132.75M	173.97M
Biosecurity Service Revenue	24.53M	37.41M	53.07M
Total Biosecurity Revenue	24.53M	37.41M	53.07M
Revenue (Other)	-7.67M	-	-
Revenue (Total)	111.86M	170.16M	227.04M

EBIT

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cell Engineering Operating Income	-183.93M	-95.53M	-218.57M
Biosecurity Operating Income	-29.67M	-18.93M	-30.62M
Corporate Operating Income	-	-200.82M	-310.57M
Operating Income (Other)	-77.09M	-	-
Operating Income (Total)	-290.69M	-315.28M	-559.76M

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
New Programs	52.00
Current Active Programs	176.00
Cumulative Programs	294.00

Data Source: Fiscal.ai Last updated: Aug 6, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 28, 2026

Data Sources Report a data error